Adicet Bio (1IJA) Price & Analysis

Compare

0 Followers

1IJA Stock Chart & Stats

Day’s Range― - ―

52-Week Range€0.34 - €1.34

Previous CloseN/A

Volume2.82K

Average Volume (3M)465.00

Market Cap

$62.57M

Enterprise Value-€54.04M

Total Cash (Recent Filing)$34.72M

Total Debt (Recent Filing)$15.36M

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Nov 05, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding83,253,780

10 Day Avg. Volume53

30 Day Avg. Volume465

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.86

Enterprise Value/Revenue-8.31

Enterprise Value/Gross Profit33.38

Enterprise Value/Ebitda0.46

Forecast

1Y Price Target

$4.47

Price Target Upside539.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

EarningsA BUY rating and $8 Price Target for Adicet shares are maintained, based on a positive outlook for ADI-001 in autoimmune disease.

Operational StrategyThe cash position of the company is strong, which supports its operational stability.

Regulatory ProgressADI-001 has been granted FDA Fast Track Designation for the treatment of adult patients with refractory systemic lupus erythematosus, systemic sclerosis, and relapsed or refractory class III or class IV lupus nephritis.

Bears Say

Competitive LandscapeThe extremely competitive nature of the landscape for ADI-001 in autoimmune diseases is noted.

Workforce ReductionThe management recently announced a reduction in its workforce by approximately 30%.

Adicet Bio News

Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating

Adicet Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from...

1M ago

ACET

Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ACET stock, giving a Buy rating yesterday. Soumit...

1M ago

ACET

Adicet Bio Reports Q2 2025 Financial Results

Adicet Bio Inc ( ($ACET) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ACET

Adicet Bio reports Q2 EPS (34c), consensus (30c)

“We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing...

1M ago

ACET

Promising Pipeline and FDA Fast Track Designations Justify Buy Rating for Adicet Bio

Adicet Bio (ACET) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns’s...

2M ago

ACET

Adicet Bio doses first patient in second cohort of ADI-001 trial

Adicet Bio (ACET) announced that the first systemic sclerosis patient has been dosed in the second cohort of...

2M ago

ACET

Adicet Bio Announces 30% Workforce Reduction Strategy

An announcement from Adicet Bio ( ($ACET) ) is now available. On July 22, 2025, Adicet Bio‘s Board...

2M ago

ACET

Adicet Bio assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns assumed coverage of Adicet Bio (ACET) with a Buy rating and $4 price...

2M ago

ACET

Adicet Bio Elects Directors and Approves Key Proposals

Adicet Bio ( ($ACET) ) just unveiled an announcement. On June 11, 2025, Adicet Bio, Inc. held its...

3M ago

ACET

Adicet Bio’s Innovative Approach and Strong Financial Position Drive Buy Rating

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Adicet Bio (ACET – Research Report). The...

3M ago

ACET

Adicet Bio participates in a conference call with Truist

Conference call with management will be held on May 19 hosted by Truist. Webcast Link Published first on...

4M ago

ACET

Adicet Bio’s Innovative Cell Therapy Programs and Strategic Focus Highlight Promising Growth Potential

JonesTrading analyst Soumit Roy maintained a Buy rating on Adicet Bio (ACET – Research Report) today and set...

4M ago

ACET

Adicet Bio’s Promising Pipeline and Strategic Developments Earn Buy Rating

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio (ACET – Research Report) and...

4M ago

ACET

Adicet Bio Reports Q1 2025 Results and Updates

Adicet Bio Inc ( ($ACET) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

ACET

1IJA FAQ

What was Adicet Bio’s price range in the past 12 months?

Adicet Bio lowest stock price was €0.34 and its highest was €1.34 in the past 12 months.

What is Adicet Bio’s market cap?

Adicet Bio’s market cap is $62.57M.

When is Adicet Bio’s upcoming earnings report date?

Adicet Bio’s upcoming earnings report date is Nov 05, 2025 which is in 52 days.

How were Adicet Bio’s earnings last quarter?

Adicet Bio released its earnings results on Aug 07, 2025. The company reported -€0.291 earnings per share for the quarter, missing the consensus estimate of -€0.26 by -€0.031.

Is Adicet Bio overvalued?

According to Wall Street analysts Adicet Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adicet Bio pay dividends?

Adicet Bio does not currently pay dividends.

What is Adicet Bio’s EPS estimate?

Adicet Bio’s EPS estimate is -0.25.

How many shares outstanding does Adicet Bio have?

Adicet Bio has 83,253,780 shares outstanding.

What happened to Adicet Bio’s price movement after its last earnings report?

Adicet Bio reported an EPS of -€0.291 in its last earnings report, missing expectations of -€0.26. Following the earnings report the stock price went down -2.359%.

Which hedge fund is a major shareholder of Adicet Bio?

Currently, no hedge funds are holding shares in DE:1IJA

Adicet Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.39%

Trailing 12-Months

Asset Growth

-39.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adicet Bio

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Adicet Bio (1IJA) Earnings & Revenues

Historic Earnings Reports

1IJA Stock 12 Month Forecast

Average Price Target

€4.47

▲(539.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.81683008,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.47354474,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.40841504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.549,1.0311407753846153,1.5132815507692308,1.9954223261538462,2.4775631015384616,2.9597038769230766,3.441844652307692,3.9239854276923074,4.406126203076923,4.888266978461538,5.370407753846154,5.852548529230769,6.3346893046153845,{"y":6.81683008,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.549,0.850888056923077,1.152776113846154,1.454664170769231,1.7565522276923078,2.0584402846153846,2.360328341538462,2.662216398461539,2.9641044553846156,3.2659925123076925,3.5678805692307693,3.8697686261538466,4.1716566830769235,{"y":4.47354474,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.549,0.7689550030769231,0.9889100061538463,1.2088650092307693,1.4288200123076924,1.6487750153846155,1.8687300184615387,2.0886850215384616,2.308640024615385,2.5285950276923077,2.748550030769231,2.968505033846154,3.188460036923077,{"y":3.40841504,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.255,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.229,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.145,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.013,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.826,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.793,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.764,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.617,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.624,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.512,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.593,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.549,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >